Protagenic Therapeutics (PTIX) - Total Liabilities
Based on the latest financial reports, Protagenic Therapeutics (PTIX) has total liabilities worth $6.82 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Protagenic Therapeutics - Total Liabilities Trend (1995–2025)
This chart illustrates how Protagenic Therapeutics's total liabilities have evolved over time, based on quarterly financial data. See PTIX current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Protagenic Therapeutics Competitors by Total Liabilities
The table below lists competitors of Protagenic Therapeutics ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CENTURION MINERALS L. NEW
F:XJC0
|
Germany | €2.37 Million |
|
Brain+ ApS
CO:BRAINP
|
Denmark | Dkr20.90 Million |
|
Vivanco Gruppe AG
F:VG0K
|
Germany | €23.05 Million |
|
Maven Income And Growth Vct 5 Plc
LSE:MIG5
|
UK | GBX1.16 Million |
|
Prima Moda SA
WAR:PMA
|
Poland | zł10.61 Million |
|
Crystal Amber Fund Limited
LSE:CRS
|
UK | GBX354.05K |
Liability Composition Analysis (1995–2025)
This chart breaks down Protagenic Therapeutics's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see PTIX company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.34 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.85 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Protagenic Therapeutics's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Protagenic Therapeutics (1995–2025)
The table below shows the annual total liabilities of Protagenic Therapeutics from 1995 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $6.82 Million | +623.81% |
| 2024-12-31 | $942.76K | +43.88% |
| 2023-12-31 | $655.25K | -41.49% |
| 2022-12-31 | $1.12 Million | +0.17% |
| 2021-12-31 | $1.12 Million | -44.90% |
| 2020-12-31 | $2.03 Million | +37.41% |
| 2019-12-31 | $1.48 Million | +62.67% |
| 2018-12-31 | $907.77K | +61.61% |
| 2017-12-31 | $561.69K | -17.98% |
| 2016-12-31 | $684.86K | -2.72% |
| 2015-12-31 | $704.00K | +11.75% |
| 2015-06-30 | $630.00K | +99.37% |
| 2014-12-31 | $316.00K | 0.00% |
| 2013-12-31 | $316.00K | -98.26% |
| 2012-12-31 | $18.18 Million | +62.76% |
| 2010-12-31 | $11.17 Million | -41.98% |
| 2009-12-31 | $19.25 Million | -20.17% |
| 2008-12-31 | $24.11 Million | +239.73% |
| 2007-12-31 | $7.10 Million | +66.19% |
| 2006-12-31 | $4.27 Million | +4421.01% |
| 2005-12-31 | $94.47K | -97.76% |
| 2004-12-31 | $4.21 Million | -51.88% |
| 2003-12-31 | $8.76 Million | +1.21% |
| 2002-12-31 | $8.65 Million | -10.83% |
| 2001-12-31 | $9.71 Million | +7.12% |
| 2000-12-31 | $9.06 Million | -6.18% |
| 1999-12-31 | $9.66 Million | +28.28% |
| 1998-12-31 | $7.53 Million | +204.82% |
| 1997-12-31 | $2.47 Million | -55.33% |
| 1996-12-31 | $5.53 Million | +54.90% |
| 1995-12-31 | $3.57 Million | -- |
About Protagenic Therapeutics
Protagenic Therapeutics, Inc. operates as a pharmaceutical company specializing in the development of medicines manufactured from cannabinoid and cannabinoid-like molecules. Protagenic Therapeutics, Inc. was founded in 2004 and is based in Santa Barbara, California.